At Recipharm, we have certainly had to make rapid adjustments to deal with the changes we have faced. When the first wave of the pandemic hit, India and Northern Italy emerged as two of its epicentres – areas where Recipharm has significant operations. It was crucial for us to respond quickly. We implemented a business continuity plan to overcome the operational challenges and to mitigate the supply chain disruption caused by the global lockdown.
We also had to consider how we would protect the wellbeing of our colleagues operating production lines. During the first wave of the outbreak, for example, the shortage of APIs caused by the closure of Chinese factories had to be managed and mitigated to maintain the international supply of vital medicines.
In an article with The Medicine Maker, our Executive Vice President, Corporate Development, Mark Quick shared his views on the challenges the small molecule sector has faced – and the sector’s outlook for 2021.